SCHEMBL7920033

SCHEMBL7920033

CCOC(=O)c1cc2nc(Br)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.58
KDM4E B2RXH2 3/20 0.58
ALDH1A1 P00352 3/20 0.58
HPGD P15428 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HSD17B10 Q99714 1/20 0.58
NPC1 O15118 2/20 0.54
LMNA P02545 2/20 0.54
HTT P42858 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HRH3 Q9Y5N1 1/20 0.54
MEN1 O00255 1/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 1/20 0.53
ATM Q13315 1/20 0.53
MMP13 P45452 8/20 0.53
MMP2 P08253 6/20 0.53
MMP14 P50281 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31609642 1.00 RAB9A (0.58) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3707866 0.86 RAB9A (0.61) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2109109 0.85 RAB9A (0.60) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3961035 0.83 KDM4E (0.58) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1202083 0.83 ALOX15 (0.59) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL30296802 0.83 ALOX15 (0.59) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL30104780 0.80 KDM4E (0.54) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL831147 0.80 KDM4E (0.54) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3253892 0.80 ALOX15 (0.55) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31058674 0.80 ALOX15 (0.55) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
EP-4653437-A2 NOVEL HETEROCYCLIC COMPOUNDS Innovo Therapeutics Inc. (KR) 2025-11-26 EP disclosed
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-05 US disclosed
EP-4482583-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-01-01 EP disclosed
WO-2024154979-A2 NOVEL HETEROCYCLIC COMPOUNDS 주식회사 이노보테라퓨틱스 2024-07-25 WO disclosed
WO-2023161316-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-31 WO disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
US-11254671-B2 Chemical compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-02-22 US disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed
US-20210163472-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-06-03 US disclosed
US-8785489-B2 Heteroaryl substituted indole compounds useful as MMP-13 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-22 US disclosed
US-8785489-B2 Heteroaryl substituted indole compounds useful as MMP-13 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-22 US disclosed
US-20110275631-A1 Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 US disclosed
US-20110275631-A1 Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 US disclosed
WO-2010045188-A1 HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS MRPL21, WIZ, CFTR RAB9A 41/4885KDM4E 4289/4885ALDH1A1 3401/4885
US-20210163472-A1 CHEMICAL COMPOUNDS MTOR, RICTOR, RPTOR RAB9A 499/4885KDM4E 983/4885ALDH1A1 2417/4885
US-11254671-B2 Chemical compounds MTOR, RICTOR, RPTOR RAB9A 499/4885KDM4E 983/4885ALDH1A1 2417/4885
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL RAB9A 1781/4885KDM4E 224/4885ALDH1A1 172/4885
US-20110275631-A1 Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors MMP13, MMP3, MMP11 RAB9A 1323/4885KDM4E 2155/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.